Is LH a good stock to buy right now?

Based on our 6-factor quantitative model, LABCORP HOLDINGS INC. (LH) receives a "Hold" rating with a composite score of 49.6/100. It is ranked #591 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 63/100, Momentum 51/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for LH?

LABCORP HOLDINGS INC. (LH) has a "Hold" rating and 3-star score. The composite score of 49.6 ranks it #591 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is LH in?

LABCORP HOLDINGS INC. operates in the Healthcare sector (Healthcare industry) with a market cap of $22.47 billion. It is classified as a large-cap stock.

Does LH pay a dividend?

Yes, LH pays a dividend with a current yield of 1.01%. For every $1,000 invested, you would receive approximately $10.10 in annual dividend income.

What is LH's P/E ratio?

LH has a trailing P/E ratio of 25.65x. The Healthcare sector average is 23.6x. This P/E is in a moderate range relative to the broader market.

How profitable is LH?

LH's quality factor score is 50/100. Gross margin: 28.6%. ROE: 10.2% vs sector average -43.5%. Margins are moderate to low, reflecting competitive market dynamics.

How is LH valued compared to peers?

LH's value factor score is 63/100 (higher = cheaper). Key multiples: P/E 25.6x, EV/EBITDA 16.5x. The stock appears attractively valued versus peers.

What is LH's debt level?

LH's debt-to-equity ratio is 113%. Sector average: 32%. Moderate leverage is normal for established companies.

LH has a beta of 0.55, meaning it is less volatile than the market. Stability score: 88/100.

Does LH have high short interest?

LH's short interest factor score is 9/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

LH Stock Analysis: Hold (Score 49.6/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
LH	-4.51%	-4.67%	-2.89%	+4.01%	+19.36%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-4.45%	-8.28%	-3.23%	+4.37%	-10.17%	-	-	-
Alpha vs Sector	-3.16%	-5.01%	+0.92%	+8.84%	+10.15%	-	-	-

Metric	LH	Benchmark
P/E Ratio	25.6x	+9%
EV/EBITDA	16.5x	+160%
Price / Book	2.6x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	44.9x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	28.1x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	16.2x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.7x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.9x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.4x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
LH LABCORP HOLDINGS INC.	50	50	63	51	25.7x	10.2%	28.6%	6.4%	10.6%	113.0x	$22.5B
PFE PFIZER INC	49	50	59	48	11.2x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.4%	0.3%	0.3%	0.3%	0.3%
Operating Margin %	0.1%	0.1%	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%
EBITDA Margin %	0.1%	0.1%	0.1%	0.1%	0.1%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Net Margin %	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
FCF Margin %	3.2%	-	-	-	-	-	12.5%	9.0%	8.2%	11.5%	9.6%
ROE %	0.1%	0.1%	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%	0.1%	0.2%	0.1%
ROA %	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%
ROIC %	7.9%	12.7%	10.7%	7.3%	13.9%	25.1%	13.9%	7.8%	8.3%	7.8%	9.2%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.3%

0.4%

0.3%

Operating Margin %

0.1%

0.2%

0.1%

EBITDA Margin %

0.1%

0.2%

Net Margin %

0.1%

0.0%

0.1%

FCF Margin %

3.2%

12.5%

9.0%

8.2%

11.5%

9.6%

ROE %

0.1%

0.2%

0.1%

0.2%

0.1%

ROA %

0.0%

0.1%

0.0%

0.1%

ROIC %

7.9%

12.7%

10.7%

7.3%

13.9%

25.1%

13.9%

7.8%

8.3%

7.8%

9.2%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$13.7B	$14.0B	$13.0B	$12.2B	$14.9B	$16.1B	$14.0B	$11.6B	$11.3B	$10.3B	$9.6B	$8.7B
	—	$9.9B	$9.4B	$8.8B	$10.5B	$10.5B	—	—	—	—	—	—
	$3.9B	$4.0B	$3.6B	$3.4B	$4.4B	$5.6B	$5.0B	$3.3B	$3.2B	$3.1B	$2.9B	$2.9B
Gross Margin	28.6%	28.8%	27.9%	27.7%	29.5%	34.9%	35.4%	28.1%	28.0%	30.0%	29.9%	33.5%
	—	$2.2B	$2.2B	$2.0B	$2.0B	$2.0B	—	—	—	—	—	—
Depreciation	—	—	—	—	—	—	$825M	$771M	$552M	$533M	$499M	$458M
Total Operating Expenses	—	$2.6B	$2.5B	$2.6B	$2.6B	$2.4B	—	—	—	—	—	—
	$1.4B	$1.4B	$1.1B	$726M	$1.8B	$3.3B	$2.4B	$1.3B	$1.3B	$1.3B	$1.3B	$1.0B
EBIT	$991M	$1.4B	$1.1B	$726M	$1.8B	$3.3B	$2.4B	$1.3B	$1.3B	$1.3B	$1.3B	$1.0B
EBITDA	$1.4B	$1.4B	$1.1B	$726M	$1.8B	$3.3B	$3.2B	$2.1B	$2.0B	$1.8B	$1.8B	$1.4B
Operating Margin	10.0%	9.9%	8.3%	6.0%	11.9%	20.2%	17.5%	11.5%	11.7%	12.7%	13.3%	11.5%
EBITDA Margin	10.0%	9.9%	8.4%	6.0%	11.9%	20.2%	23.2%	18.2%	18.0%	17.8%	18.7%	16.7%
	—	$224M	$208M	$200M	$180M	$212M	$207M	$241M	$244M	$235M	$219M	$275M
	—	$14.0B	$13.0B	$12.2B	$14.9B	$16.1B	—	—	—	—	—	—
Income Tax Expense	—	$230M	$212M	$189M	$302M	$747M	$662M	$280M	$384M	-$155M	$361M	$294M
	$882M	$878M	$747M	$419M	$1.3B	$2.4B	$1.6B	$825M	$884M	$1.2B	$713M	$438M
Net Margin	6.4%	6.3%	5.7%	3.5%	8.6%	14.8%	11.1%	7.1%	7.8%	12.0%	7.5%	5.1%
	$10.54	$10.54	$8.89	$4.80	$14.05	$24.60	-	-	-	-	-	-
Diluted EPS	$10.54	$10.46	$8.84	$4.77	$13.97	$24.39	-	-	-	-	-	-
Weighted Avg Basic	—	83M	84M	87M	91M	97M	—	—	—	—	—	—
Weighted Avg Diluted	—	84M	84M	88M	92M	98M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$13.7B

$14.0B

$13.0B

$12.2B

$14.9B

$16.1B

$14.0B

$11.6B

$11.3B

$10.3B

$9.6B

$8.7B

—

$9.9B

$9.4B

$8.8B

$10.5B

—

$3.9B

$4.0B

$3.6B

$3.4B

$4.4B

$5.6B

$5.0B

$3.3B

$3.2B

$3.1B

$2.9B

Gross Margin

28.6%

28.8%

27.9%

27.7%

29.5%

34.9%

35.4%

28.1%

28.0%

30.0%

29.9%

33.5%

—

$2.2B

$2.0B

—

Depreciation

—

$825M

$771M

$552M

$533M

$499M

$458M

Total Operating Expenses

—

$2.6B

$2.5B

$2.6B

$2.4B

—

$1.4B

$1.1B

$726M

$1.8B

$3.3B

$2.4B

$1.3B

$1.0B

EBIT

$991M

$1.4B

$1.1B

$726M

$1.8B

$3.3B

$2.4B

$1.3B

$1.0B

EBITDA

$1.4B

$1.1B

$726M

$1.8B

$3.3B

$3.2B

$2.1B

$2.0B

$1.8B

$1.4B

Operating Margin

10.0%

9.9%

8.3%

6.0%

11.9%

20.2%

17.5%

11.5%

11.7%

12.7%

13.3%

11.5%

EBITDA Margin

10.0%

9.9%

8.4%

6.0%

11.9%

20.2%

23.2%

18.2%

18.0%

17.8%

18.7%

16.7%

—

$224M

$208M

$200M

$180M

$212M

$207M

$241M

$244M

$235M

$219M

$275M

—

$14.0B

$13.0B

$12.2B

$14.9B

$16.1B

—

Income Tax Expense

—

$230M

$212M

$189M

$302M

$747M

$662M

$280M

$384M

-$155M

$361M

$294M

$882M

$878M

$747M

$419M

$1.3B

$2.4B

$1.6B

$825M

$884M

$1.2B

$713M

$438M

Net Margin

6.4%

6.3%

5.7%

3.5%

8.6%

14.8%

11.1%

7.1%

7.8%

12.0%

7.5%

5.1%

$10.54

$8.89

$4.80

$14.05

$24.60

Diluted EPS

$10.54

$10.46

$8.84

$4.77

$13.97

$24.39

Weighted Avg Basic

—

83M

84M

87M

91M

97M

—

Weighted Avg Diluted

—

84M

88M

92M

98M

—

LABCORP HOLDINGS INC. (LH) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does LABCORP HOLDINGS INC. Do?

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina. LABCORP HOLDINGS INC. (LH) is classified as a large-cap stock in the Healthcare sector. The company is led by CEO Adam H. Schechter and employs approximately 75,500 people, headquartered in Burlington, North Carolina. With a market capitalization of $22.5B, LH is one of the prominent companies in the Healthcare sector.

LABCORP HOLDINGS INC. (LH) Stock Rating — Hold (April 2026)

As of April 2026, LABCORP HOLDINGS INC. receives a Hold rating with a composite score of 49.6/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.LH ranks #591 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, LABCORP HOLDINGS INC. ranks #30 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LH Stock Price and 52-Week Range

LABCORP HOLDINGS INC. (LH) currently trades at $260.93. The stock lost $12.33 (4.5%) in the most recent trading session. The 52-week high for LH is $293.72, which means the stock is currently trading -11.2% from its annual peak. The 52-week low is $209.38, putting the stock 24.6% above its annual trough. Recent trading volume was 797K shares, suggesting relatively thin trading activity.

Is LH Overvalued or Undervalued? — Valuation Analysis

LABCORP HOLDINGS INC. (LH) carries a value factor score of 63/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 25.65x, compared to the Healthcare sector average of 23.63x — a premium of 9%. The price-to-book ratio stands at 2.63x, versus the sector average of 2.75x. The price-to-sales ratio is 1.65x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, LH trades at 16.51x EV/EBITDA, versus 6.34x for the sector. The EV/EBIT multiple is 22.84x.

Overall, LH's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

LABCORP HOLDINGS INC. Profitability — ROE, Margins, and Quality Score

LABCORP HOLDINGS INC. (LH) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 10.2%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 4.8% versus the sector average of -33.1%.

On a margin basis, LABCORP HOLDINGS INC. reports gross margins of 28.6%, compared to 71.5% for the sector. The operating margin is 10.0% (sector: -66.1%). Net profit margin stands at 6.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 10.6% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

LH Debt, Balance Sheet, and Financial Health

LABCORP HOLDINGS INC. has a debt-to-equity ratio of 113.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.42x, suggesting adequate working capital coverage. Total debt on the balance sheet is $5.65B. Cash and equivalents stand at $598M.

LH has a beta of 0.55, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for LABCORP HOLDINGS INC. is 88/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

LABCORP HOLDINGS INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, LABCORP HOLDINGS INC. reported revenue of $13.72B and earnings per share (EPS) of $10.54. Net income for the quarter was $882M. Gross margin was 28.6%. Operating income came in at $1.37B.

In FY 2025, LABCORP HOLDINGS INC. reported revenue of $13.95B and earnings per share (EPS) of $10.54. Net income for the quarter was $878M. Gross margin was 28.8%. Revenue grew 7.2% year-over-year compared to FY 2024. Operating income came in at $1.38B.

In Q3 2025, LABCORP HOLDINGS INC. reported revenue of $3.56B and earnings per share (EPS) of $3.14. Net income for the quarter was $262M. Gross margin was 28.8%. Revenue grew 8.6% year-over-year compared to Q3 2024. Operating income came in at $397M.

In Q2 2025, LABCORP HOLDINGS INC. reported revenue of $3.53B and earnings per share (EPS) of $2.85. Net income for the quarter was $238M. Gross margin was 29.7%. Revenue grew 9.5% year-over-year compared to Q2 2024. Operating income came in at $395M.

Over the past 8 quarters, LABCORP HOLDINGS INC. has demonstrated a growth trajectory, with revenue expanding from $3.22B to $13.72B. Investors analyzing LH stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LH Dividend Yield and Income Analysis

LABCORP HOLDINGS INC. (LH) currently pays a dividend yield of 1.0%. At this yield, a $10,000 investment in LH stock would generate approximately $$101.00 in annual dividend income. The net margin of 6.4% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.

LH Momentum and Technical Analysis Profile

LABCORP HOLDINGS INC. (LH) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 29/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 9/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

LH vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, LABCORP HOLDINGS INC. (LH) ranks #30 out of 838 stocks based on the Blank Capital composite score. This places LH in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LH against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LH vs S&P 500 (SPY) comparison to assess how LABCORP HOLDINGS INC. stacks up against the broader market across all factor dimensions.

LH Next Earnings Date

No upcoming earnings date has been announced for LABCORP HOLDINGS INC. (LH) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LH? — Investment Thesis Summary

LABCORP HOLDINGS INC. presents a balanced picture with arguments on both sides. The value score of 63/100 suggests attractive pricing relative to fundamentals. Low volatility (stability score 88/100) reduces downside risk.

In summary, LABCORP HOLDINGS INC. (LH) earns a Hold rating with a composite score of 49.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LH stock.

Related Resources for LH Investors

Explore more research and tools: LH vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LH head-to-head with peers: LH vs AZN, LH vs SLGL, LH vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Labcorp Holdings Inc. stock underperforms Friday when compared to competitors

Labcorp Holdings Inc. stock underperforms Tuesday when compared to competitors

Labcorp Holdings Inc. stock outperforms competitors on strong trading day

Exosomes Market Evolution (2026) | Nano Vesicles, Liquid Biopsy, Oncology Research & Biotech Investments | Top Companies 2026 - Miltenyi Biotec, Novus Biologicals, Capital Biosciences, and Bio Techne

Labcorp Holdings Inc. stock rises Wednesday, still underperforms market

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

LABCORP HOLDINGS INC. (LH) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does LABCORP HOLDINGS INC. Do?

LABCORP HOLDINGS INC. (LH) Stock Rating — Hold (April 2026)

LH Stock Price and 52-Week Range

Is LH Overvalued or Undervalued? — Valuation Analysis

LABCORP HOLDINGS INC. Profitability — ROE, Margins, and Quality Score

LH Debt, Balance Sheet, and Financial Health

LABCORP HOLDINGS INC. Revenue and Earnings History — Quarterly Trend

LH Dividend Yield and Income Analysis

LH Momentum and Technical Analysis Profile

LH vs Competitors — Healthcare Sector Ranking and Peer Comparison

LH Next Earnings Date

Should You Buy LH? — Investment Thesis Summary

Related Resources for LH Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Labcorp Holdings Inc. stock underperforms Friday when compared to competitors

Labcorp Holdings Inc. stock underperforms Tuesday when compared to competitors

Labcorp Holdings Inc. stock outperforms competitors on strong trading day

Exosomes Market Evolution (2026) | Nano Vesicles, Liquid Biopsy, Oncology Research & Biotech Investments | Top Companies 2026 - Miltenyi Biotec, Novus Biologicals, Capital Biosciences, and Bio Techne

Labcorp Holdings Inc. stock rises Wednesday, still underperforms market